Avid Bioservices | Evaluate

October 12, 2016

Esmo event analyser – Tesaro tops the risers while Bristol-Myers is battered

Revisiting a predictor of failure in the post-Celator world

January 12, 2016

JP Morgan – Jumping in front of the cancer immunotherapy parade

April 22, 2015

Growth of anti-PD1 therapy threatens traditional second line chemo in NSCLC

June 28, 2013

Peregrine fails again and looks forward to phase III

January 08, 2013

Now you see it, now you don’t: Peregrine’s bavi might work after all

November 29, 2012

The curious solution to Curis’s pipeline conundrum

September 27, 2012

Peregrine crashes to earth after loan default

September 25, 2012

Peregrine's bavi dream turns into a nightmare

September 10, 2012

Peregrine’s bavi data: too good to be true?

August 17, 2012

Therapeutic Focus – Avastin provides glimmer in glioblastoma but progress still slow

Load More